02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
23:04 , Oct 26, 2018 |  BC Extra  |  Politics & Policy

FDA grants first qualification of a clinical safety biomarker

FDA qualified a group of kidney injury biomarkers from the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) and the Critical Path Institute (C-Path) Predictive Safety Testing Consortium (PSTC), marking the first...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
19:10 , Jun 14, 2017 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Diagnostic assays A strain of E. coli engineered to express a synthetic gene circuit that detects the reactive oxygen species (ROS)-derivative tetrathionate could be used to diagnose intestinal inflammation in vivo . The synthetic...
22:30 , Mar 16, 2017 |  BC Innovations  |  Targets & Mechanisms

Bone appétit!

Last week’s Nature publication of a hormone secreted by bone that suppresses appetite and can curb weight gain not only adds to the emerging picture of bone as a player in the endocrine system but...
12:54 , Mar 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity Mouse studies suggest LCN2 could help treat obesity. In a mouse model of obesity, LCN2 decreased food intake, body fat mass and weight gain compared with vehicle. Next steps include longer-term studies to...
18:52 , Jan 12, 2017 |  BC Innovations  |  Translation in Brief

Iron age arms race

Two research groups have turned bacteria’s own survival mechanisms against them with therapeutic vaccines based on siderophores - iron-scavenging molecules the pathogens secrete that are not ordinarily immunogenic. The preclinical studies showed conjugating siderophores to...
19:59 , Dec 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Hematology Mouse studies suggest an NGAL -enterobactin complex could help treat iron overload caused by chronic blood transfusion, hemochromatosis and other disorders. The complex consisted of the iron-chelating molecule enterobactin bound to a human...
07:00 , Jul 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Lipocalin (NGAL; LCN2)

Cancer INDICATION: Breast cancer Mouse studies suggest inhibiting NGAL could help treat breast cancer. In a mouse model of metastatic breast cancer, systemic NGAL knockout decreased the number of metastases in the lungs and levels...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

NGAL Test regulatory update

BioPorto said it will continue to seek FDA approval of its NGAL Test to detect acute kidney injury following discussions with the agency and anticipates “approval within 18-24 months.” In late May, FDA rejected the...